JP5757483B2 - 抗体性拒絶反応抑制剤 - Google Patents
抗体性拒絶反応抑制剤 Download PDFInfo
- Publication number
- JP5757483B2 JP5757483B2 JP2011511287A JP2011511287A JP5757483B2 JP 5757483 B2 JP5757483 B2 JP 5757483B2 JP 2011511287 A JP2011511287 A JP 2011511287A JP 2011511287 A JP2011511287 A JP 2011511287A JP 5757483 B2 JP5757483 B2 JP 5757483B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cells
- cd1d
- mouse
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title claims description 22
- 102000036639 antigens Human genes 0.000 claims description 45
- 108091007433 antigens Proteins 0.000 claims description 45
- 239000008280 blood Substances 0.000 claims description 44
- 239000000427 antigen Substances 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 33
- 238000004519 manufacturing process Methods 0.000 claims description 31
- 210000004369 blood Anatomy 0.000 claims description 27
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 26
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 24
- 238000002054 transplantation Methods 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 230000019491 signal transduction Effects 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000002689 xenotransplantation Methods 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 33
- 230000003053 immunization Effects 0.000 description 30
- 238000002649 immunization Methods 0.000 description 29
- 238000012360 testing method Methods 0.000 description 16
- 238000011813 knockout mouse model Methods 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 description 10
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 230000016784 immunoglobulin production Effects 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 102000006306 Antigen Receptors Human genes 0.000 description 4
- 108010083359 Antigen Receptors Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 3
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 3
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 101710123661 Venom allergen 5 Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 229940046731 calcineurin inhibitors Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- QIGJYVCQYDKYDW-SDOYDPJRSA-N alpha-D-galactosyl-(1->3)-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-SDOYDPJRSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Description
NKT細胞の血液型糖鎖抗原に対する抗体産生への影響を解析するため、Balb/c CD1d−/−マウス(iTCRのリガンドであるCD1dを欠き、NKT細胞が顕著に減少していることが知られているマウス;ノックアウトマウス、n=4)と、比較対照のBalb/c野生種マウス(n=5)とをヒトA型赤血球(8×108/マウス)で免疫し、抗血液型A抗体産生をELISAを用いて測定した。
NKT細胞の通常のペプチド抗原に対する抗体産生の影響を解析するため、上記ノックアウトマウスと、Balb/c野生種マウス(MHCハプロタイプd)とをそれぞれC57BL/6野生型マウス(MHCハプロタイプb)の胸腺細胞(20×106/マウス)で免疫し、抗アロMHC抗体の産生量をフローサイトメーターを用いて測定した(n=6、比較対照として未処理群:n=3)。
NKT細胞とB-1細胞との間のシグナル伝達を抗CD1d抗体で阻害することにより抗血液型抗体の産生を抑制できるか否かを解析するため、Balb/c野生型マウスに抗CD1d抗体(rat anti-mouse CD1d monoclonal antibody、clone:1B1)をマウス1匹当たり450μg腹腔内投与した(テストマウス、n=3)。また、同様にrat IgG2b抗体(isotype control)をマウス1匹当たり450μg腹腔内投与した(対照マウス、n=3)。
ヒトの場合においても上述したマウスの場合と同様の効果が得られることを確認するため、ヒトリンパ球キメラマウスを用いて試験を行った。
2 B-1細胞
3 抗CD1d抗体
4 CD1d分子
5 糖鎖抗原
6 抗原レセプター
7 iTCR
8 抗体
Claims (5)
- 異種移植を対象としない抗体性拒絶反応抑制剤であって、
抗CD1d抗体を含み、
NKT細胞とB細胞との間のシグナル伝達を前記抗CD1d抗体で阻害することにより、ペプチド抗原に対する抗体の産生を抑制しないで、ヒト由来の血液型糖鎖抗原に対する抗体の産生を特異的に抑制することを特徴とする抗体性拒絶反応抑制剤。 - 請求項1に記載の抗体性拒絶反応抑制剤であって、
前記B細胞がB-1細胞を含む抗体性拒絶反応抑制剤。 - 請求項1に記載の抗体性拒絶反応抑制剤であって、
前記抗CD1d抗体がモノクローナル抗体である抗体性拒絶反応抑制剤。 - 請求項3に記載の抗体性拒絶反応抑制剤であって、
前記抗CD1d抗体がヒト型抗体である抗体性拒絶反応抑制剤。 - 請求項1に記載の抗体性拒絶反応抑制剤であって、
血液型の異なるドナーからの移植に用いられる抗体性拒絶反応抑制剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011511287A JP5757483B2 (ja) | 2009-04-30 | 2010-04-19 | 抗体性拒絶反応抑制剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009110887 | 2009-04-30 | ||
JP2009110887 | 2009-04-30 | ||
PCT/JP2010/002825 WO2010125762A1 (ja) | 2009-04-30 | 2010-04-19 | 抗体性拒絶反応抑制剤 |
JP2011511287A JP5757483B2 (ja) | 2009-04-30 | 2010-04-19 | 抗体性拒絶反応抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2010125762A1 JPWO2010125762A1 (ja) | 2012-10-25 |
JP5757483B2 true JP5757483B2 (ja) | 2015-07-29 |
Family
ID=43031922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011511287A Active JP5757483B2 (ja) | 2009-04-30 | 2010-04-19 | 抗体性拒絶反応抑制剤 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20120046452A1 (ja) |
JP (1) | JP5757483B2 (ja) |
WO (1) | WO2010125762A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001512438A (ja) * | 1997-02-11 | 2001-08-21 | イムノメディクス,インコーポレイテッド | αガラクトシルエピトープで標識された抗体による免疫応答の刺激 |
JP2004500154A (ja) * | 1999-06-03 | 2004-01-08 | アドバンスト エクストラバスキュラー システムズ | 循環血液からの好ましくない分子の一段階除去 |
JP2008546647A (ja) * | 2005-06-08 | 2008-12-25 | デューク ユニバーシティ | 移植のための抗−cd19抗体治療 |
-
2010
- 2010-04-19 US US13/318,090 patent/US20120046452A1/en not_active Abandoned
- 2010-04-19 WO PCT/JP2010/002825 patent/WO2010125762A1/ja active Application Filing
- 2010-04-19 JP JP2011511287A patent/JP5757483B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001512438A (ja) * | 1997-02-11 | 2001-08-21 | イムノメディクス,インコーポレイテッド | αガラクトシルエピトープで標識された抗体による免疫応答の刺激 |
JP2004500154A (ja) * | 1999-06-03 | 2004-01-08 | アドバンスト エクストラバスキュラー システムズ | 循環血液からの好ましくない分子の一段階除去 |
JP2008546647A (ja) * | 2005-06-08 | 2008-12-25 | デューク ユニバーシティ | 移植のための抗−cd19抗体治療 |
Non-Patent Citations (2)
Title |
---|
JPN6010035546; LIU,S. et al: Transplantation Proceedings Vol.41, No.1, 200902, p.398-402 * |
JPN6010035547; IREI,T. et al: Blood Vol.110, No.13, 2007, p.4567-75 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2010125762A1 (ja) | 2012-10-25 |
WO2010125762A1 (ja) | 2010-11-04 |
US20120046452A1 (en) | 2012-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20190117489A (ko) | 항-bcma 중쇄-단독 항체 | |
US20110318340A1 (en) | Deglycosylated antibodies | |
CN106414489A (zh) | 抗-b7-h5抗体及其用途 | |
FR2807767A1 (fr) | Anticorps monoclonaux anti-d | |
JP2019527678A (ja) | CD38に特異的に結合する抗体によるIgE媒介疾患の治療 | |
WO2020060924A1 (en) | Use of a cd4/cd8 bispecific antibody for the treatment of autoimmune/inflammatory disorders | |
US11059889B2 (en) | Anti-human Igβ antibody | |
CN102906115A (zh) | 在经抗cd200抗体治疗的人体内的免疫调节效应的生物标记 | |
JP5757483B2 (ja) | 抗体性拒絶反応抑制剤 | |
US9718891B2 (en) | Antibodies specific to a novel epitope on CεMX of human membrane-bound IgE and uses thereof in treating IgE-mediated diseases | |
JP6856183B1 (ja) | 二重特異性抗体 | |
US11084871B2 (en) | Composition with reduced immunogenicity | |
US20210198346A1 (en) | Treatment of immune diseases by means of the antibody-mediated neutralization of specific intestinal bacteria | |
CA2542508A1 (fr) | Igg3 anti rhesus-d dans la lignee yb2/0 ayant une forte activite en phagocytose | |
US20190330369A1 (en) | Combination of anti-cd303 and anti-her2 antibodies | |
CN118146376A (zh) | Hla-g抗体及其制备方法和用途 | |
CN118184783A (zh) | Hla-g抗体及其制备方法和用途 | |
Teeling | Interaction of Intravenous Immunoglobulins (IVIG) with Fc [gamma]-receptors: Activation and Inhibition of Phagocyte Functions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130417 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140401 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140530 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150406 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150415 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150512 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150525 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5757483 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |